Among immunosuppressed persons in industrialized countries, hepatitis E virus (HEV) is a cause of sporadic acute viral hepatitis and chronic hepatitis ([@R1]*,*[@R2]). In the United States, liver test results are often abnormal for HIV-infected persons; however, few studies have evaluated whether HEV is a cause of hepatitis in this population ([@R3]).

The Study
=========

We retrospectively evaluated HIV-infected persons for whom alanine aminotransferase (ALT) levels had increased acutely ([\>]{.ul}5 × the upper limit of normal) during the HIV epidemic (1985--2009). Eligible participants were US military beneficiaries (persons entitled to receive care at a military treatment facility) for whom a stored serum specimen, collected from 3 days before ALT increase through 180 days after ALT increase, was available for HEV testing. A case of acute HEV infection was defined as a sample with HEV RNA and/or IgM against HEV or evidence of IgG seroconversion. All samples collected at the time of ALT increase were tested for IgM and IgG against HEV by using commercially available enzyme immunoassays (Diagnostics Systems, Nizhniy Novgorod, Russia) ([@R4]) and PCR for HEV RNA ([@R5]). The testing strategy is shown in [Figure 1](#F1){ref-type="fig"}. All positive results were verified by retesting.

![Testing strategy for acute hepatitis E virus (HEV) infection among US military beneficiaries who had had increased alanine aminotransferase (ALT) levels during 1985--2009. +, positive; --, negative.](11-1278-F1){#F1}

Statistical analyses included descriptive statistics presented as numbers (percentages) for categorical variables and medians (interquartile ranges \[IQRs\]) for continuous variables. The percentage of participants with HEV infection was defined as the number with an initial positive result for IgM or IgG against HEV divided by the total number of evaluable study participants. To compare characteristics among those with and without HEV infection, we used Fisher exact testing for categorical variables and rank-sum testing for continuous variables. A multivariate logistic regression model was used to identify factors associated with HEV infection. All analyses were performed by using Stata version 10.0 (StataCorp LP, College Station, TX, USA).

Among 4,410 HIV-infected persons, 458 (10%) had increased ALT levels at least 1 time during 32,468 person-years of follow-up. Among these, serum samples were available for HEV testing for 194 (42%) participants, among whom median age was 34 (IQR 30--40) years, 95% were male, and 42% were white ([Table 1](#T1){ref-type="table"}). The median ALT level was 440 (IQR 322--812) IU/mL. At the ALT spike, participants had been infected with HIV for a median duration of 5 (IQR 2--9) years; median CD4 cell count was 436 (IQR 239--627) cells/mm^3^, median plasma HIV RNA level was 13,581 (IQR 762--71,586) copies/mL, and 28% of participants were receiving antiretroviral therapy.

###### Characteristics of 194 HIV-positive US military beneficiaries at time of ALT increase, 1985--2009\*

  Characteristic†                                    Total cohort     HEV seropositive,‡ n = 13   HEV seronegative, n = 181   Odds ratio   p value
  -------------------------------------------------- ---------------- --------------------------- --------------------------- ------------ ---------
  Demographics                                                                                                                             
  Age, y                                             34 (30--40)      35 (32--40)                 34 (29--40)                 1.01         0.66
  Male gender                                        185 (95)         13 (100)                    172 (95)                    --           --
  Ethnicity                                                                                                                                0.4
  White                                              82 (42)          7 (54)                      75 (41)                     Referent     
  African American                                   77 (40)          4 (31)                      73 (40)                     0.59         
  Hispanic                                           29 (15)          1 (8)                       28 (16)                     0.38         
  Other                                              6 (3)            1 (8)                       5 (3)                       2.14         
  Military status                                                                                                                          0.32
  Active duty                                        98 (50)          4 (31)                      94 (52)                     Referent     
  Retired                                            85 (44)          8 (61)                      77 (43)                     2.44         
  Spouse/dependent                                   11 (6)           1 (8)                       10 (5)                      2.35         
  Overseas travel§                                   48/127 (38)      1/5 (20)                    47/122 (39)                 0.4          0.65
  Liver function test results                                                                                                              
  Timing of blood collection after ALT increase, d   27 (0--104)      31 (7--107)                 23 (0--105)                 1.0          0.78
  ALT level, IU/L                                    440 (322--812)   367 (241--483)              454 (333--821)              0.99         0.63
  AST level, IU/L                                    262 (183--653)   297 (152--474)              260 (185--693)              1.0          0.66
  Clinical conditions                                                                                                                      
  Gonorrhea§                                         54 (28%          2 (15)                      52 (29)                     0.44         0.36
  Chlamydia/nonspecific urethritis§                  20 (10)          1 (8)                       19 (11)                     0.7          1.0
  Syphilis§                                          32 (17)          4 (31)                      28 (16)                     2.38         0.24
  Any STI§¶                                          84 (44)          6 (46)                      78 (44)                     1.1          1.0
  Hepatitis B\#                                                                                                                            
  Prior infection                                    97 (51)          8 (62)                      89 (50)                     1.6          0.57
  Chronic                                            30 (15)          3 (23)                      27 (15)                     1.69         0.43
  Hepatitis C\#                                      12 (6)           2 (15)                      10 (6)                      3.05         0.19
  HIV--specific factors                                                                                                                    
  HIV infection duration, y                          5 (1.8--8.8)     5.3 (2.3--10.0)             4.9 (1.7--8.6)              1.01         0.89
  CD4 cell count, cells/mm^3^                        436 (239--627)   217 (9--589)                439 (258--633)              0.79         0.07
  \<200                                              40 (21)          6 (46)                      34 (19)                     Referent     --
  200--499                                           80 (41)          3 (23)                      77 (42)                     0.22         0.06
  [\>]{.ul}500                                       74 (38)          4 (31)                      70 (39)                     0.32         0.10
  Median HIV RNA level, log~10~ copies/mL§           4.1 (2.9--4.9)   4.7 (3.9--5.4)              4.1 (2.9--4.8)              1.96         0.04
  HIV RNA copies/mL                                                                                                                        
  \<1,000                                            48 (27)          1 (9)                       47 (28)                     Referent     --
  1,000--10,000                                      36 (20)          2 (18)                      34 (20)                     2.76         0.57
  \>10,000                                           96 (53)          8 (73)                      88 (52)                     4.27         0.27
  Antiretroviral drug use                            55 (28)          1 (8)                       54 (30)                     0.2          0.12

\*ALT, alanine aminotransferase; HEV, hepatitis E virus; AST, aspartate aminotransferase; STI, sexually transmitted infection. †Characteristics are expressed as number (percent) for categorical variables and medians (interquartile range) for continuous variables. ‡IgM and/or IgG against HEV. §Some data were missing: for overseas travel n = 127; STIs n = 191; HIV RNA level n = 180. ¶Gonorrhea, chlamydial infection, nonspecific urethritis, or syphilis. \#Based on clinical diagnoses; similar results noted when prior hepatitis B virus infection was defined as total positive for hepatitis B virus core antigen, chronic hepatitis B infection as positive for hepatitis B virus surface antigen, and hepatitis C infection as positive for IgG against hepatitis C virus.

Samples for HEV testing were available at a median of 27 (IQR 0--104) days after the increase in ALT level. For 13 (6.7%) participants, IgM and/or IgG against HEV were present at the time closest to the ALT increase; antibody prevalence among those with elevated ALT levels did not increase during the HIV epidemic (χ^2^ 0.76, p = 0.68). The 13 HIV-infected persons who were HEV seropositive (IgM or IgG at ALT spike) were similar to the 181 who were HEV seronegative in terms of demographics, military duty status, laboratory data, and overseas travel ([Table 1](#T1){ref-type="table"}). HEV-seropositive persons had higher plasma HIV RNA levels (4.7 vs. 4.1 log~10~ copies/mL, p = 0.04) and the association with lower CD4 cell counts was borderline (median 217 vs. 439 cells/mm^3^, p = 0.07). In the multivariate logistic regression model adjusted for age, plasma HIV RNA levels remained significantly associated with HEV seropositivity (odds ratio 1.96 per log~10~, 95% CI 1.04--3.71, p = 0.04).

Additional testing was conducted for all 13 participants with IgM or IgG against HEV or with HEV RNA at the time of ALT increase ([Figure 1](#F1){ref-type="fig"}). HEV RNA was detected in 1 participant who also seroconverted (IgG) at the time of ALT increase. According to samples collected at or near ALT spike and after ALT spike, 5 more participants seroconverted. One participant had IgM detectable in all 3 samples (at or near ALT spike, after ALT spike, and at follow-up); the participant did not seroconvert, and HEV RNA was not detectable in any sample. In total, 7 (3.6%, 95% CI 1.6%--7.6%) of the 194 HIV-infected persons had evidence of acute HEV infection at time of ALT spike ([Figure 2](#F2){ref-type="fig"}). HEV was deemed not to be the cause of the ALT spike for 5 participants with evidence of prior HEV infection because IgG positivity preceded the ALT increase**.** For 1 participant, IgM was found in only 1 sample; all other samples were negative for IgM, IgG, and HEV RNA. Because of unconfirmed positive follow-up results, this participant was excluded from further analysis.

![IgM and IgG against hepatitis E virus (HEV) signal/cutoff ratios for 7 HIV-infected US military beneficiaries with acute HEV infection, 1985--2009. Serum specimens were tested for HEV markers before and after alanine aminotransferase spike, indicated by 0.0 on x-axis. Horizontal lines indicate enzyme immunoassay signal/cutoff ratio of 1.0.](11-1278-F2){#F2}

For the 7 participants with acute HEV infection ([Table 2](#T2){ref-type="table"}), HEV was not considered during the ALT increase, and HEV testing was not conducted as part of clinical care. No significant differences in clinical or laboratory characteristics were found among the 7 participants with acute HEV infection and those without evidence of HEV infection (data not shown). Chronic HEV infection did not develop in any participant.

###### Characteristics of HIV-positive US military beneficiaries with acute HEV infection at time of ALT increase, 1985--2009\*

  Patient                              1                                                           2                                                         3                                                                              4                                   5                6                  7
  ------------------------------------ ----------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------ ----------------------------------- ---------------- ------------------ --------------------------------
  Age, y                               34                                                          35                                                        35                                                                             33                                  44               41                 30
  Ethnicity                            White                                                       African-American                                          White                                                                          African-American                    White            African-American   African-American
  Duty status                          Active                                                      Retired                                                   Active                                                                         Retired                             Retired          Retired            Retired
  Year of ALT increase                 2001                                                        1995                                                      2000                                                                           2006                                1989             1996               1996
  Clinical presentation                Nausea, vomiting, abdominal pain, pale stools, dark urine   Fever, malaise, anorexia, diarrhea, dark urine, icterus   Fever, nausea, vomiting, diarrhea, abdominal pain, loss of appetite, malaise   Jaundice                            Abdominal pain   Asymp              Asymp
  Peak ALT, U/L                        489                                                         2,540                                                     282                                                                            2,829                               229              477                226
  AST, U/L                             354                                                         988                                                       174                                                                            4,273                               209              508                130
  Alkaline phosphatase, U/L            80                                                          153                                                       99                                                                             409                                 157              125                137
  Total bilirubin, mg/dL               3.2                                                         5.0                                                       1.9                                                                            5.3                                 1.6              0.5                1.2
  Antibodies against                                                                                                                                                                                                                                                                                                
  Hepatitis B virus core antigen       Neg                                                         Pos                                                       Pos                                                                            Pos                                 Neg              Pos                Pos
  Hepatitis B virus surface antigen    Neg                                                         Neg                                                       Neg                                                                            Pos                                 Neg              Pos                Neg
  Hepatitis C virus                    Neg                                                         Neg                                                       Neg                                                                            Neg                                 Neg              Neg                Pos
  History of STI since HIV Infection   None                                                        None                                                      None                                                                           Syphilis and chlamydia infections   Gonorrhea        Syphilis           Gonorrhea
  Travel overseas                      NK                                                          NK                                                        Kuwait                                                                         NK                                  NK               NK                 NK
  Duration of HIV, y                   11                                                          2                                                         \<1                                                                            13                                  2                8                  9
  CD4 count, cells/mm^3^               822                                                         517                                                       660                                                                            454                                 753              98                 217
  HIV RNA level, copies/mL             427                                                         52,929                                                    6,854                                                                          52,682                              40,000           430,946            8,068
  HAART received                       Yes                                                         No                                                        No                                                                             No                                  No               No†                No‡
  HEV serostatus                       IgG sero and HEV RNA                                        IgG sero                                                  IgM and IgG positivity                                                         IgG sero                            IgG sero         IgG sero           IgM with persistent positivity

\*All patients were male; none had evidence of acute hepatitis A virus infection or chronic HEV. HEV, hepatitis E infection; ALT, alanine aminotransferase; asymp, asymptomatic; AST, aspartate aminotransferase; neg, negative; pos, positive; STI, sexually transmitted infection; NK, none known; HAART, highly active antiretroviral therapy; sero, seroconversion. †Patient was receiving monotherapy with zalcitabine. ‡Patient was receiving dual therapy with stavudine and ritonavir.

Conclusions
===========

HEV infection accounted for 4% of acute liver abnormalities among HIV-infected persons. Overall, HEV was detected in 6% of HIV-infected participants, similar to the 5%--21% reported earlier from the United States ([@R1]*,*[@R6]). Because study participation was limited to persons who had a sample available for HEV testing near the time of ALT increase, we might have missed cases of HEV infection. Overall, on the basis of our study and data from other industrialized countries ([@R7]*,*[@R8]), HEV is a cause of liver abnormalities in HIV-infected persons but does not seem to be more common in this population than in the general population.

HEV seropositivity did not increase over the course of the HIV epidemic. Despite increasing reports of HEV among HIV-infected persons and the general population ([@R1]*,*[@R3]*,*[@R7]*--*[@R10]), this increase is probably associated with increased recognition and testing. Recent studies in the United States and Europe have shown that HEV seroprevalence is stable or decreasing ([@R1]*,*[@R11]).

HEV infections among HIV-infected persons have been reported ([@R3]*,*[@R7]*--*[@R9]*,*[@R12]); however, whether this population is at increased risk for HEV infection remains uncertain. Recent studies from Europe suggest that HIV-infected persons or other immunocompromised persons are not at increased risk of acquiring HEV infections ([@R7]*--*[@R9]*,*[@R12]). Nonetheless, these groups are at higher risk for chronic HEV infection ([@R2]*,*[@R7]*,*[@R13]).

We propose that a diagnosis of HEV infection be considered for persons with viral-like hepatitis. Serologic test results may be negative despite ongoing HEV infection; hence, for HIV-infected persons (especially those with low CD4 cell counts), PCR testing for HEV RNA should be conducted ([@R7]). Because HEV infection may be fulminant in the presence of underlying liver disease (common among HIV-infected persons) ([@R14]) and may lead to chronic infection in immunosuppressed persons ([@R2]*,*[@R13]), testing should be considered for these persons as treatment options for HEV infection evolve. Moreover, chronic HEV infection may be averted by reducing the level of immunosuppression ([@R15]) and use of highly active antiretroviral therapy ([@R3]*,*[@R8]), but more data are needed to support these measures.

HEV infection is a newly defined cause of acute liver dysfunction among HIV-infected persons in the United States. HEV infections do not seem to preferentially occur among HIV-infected persons, suggesting that HIV itself may not be a risk factor for HEV acquisition. HEV infection should be considered among HIV-infected persons with liver abnormalities of unclear etiology.
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